Associations of frailty with survival, hospitalization, functional decline, and toxicity among older adults with advanced non-small cell lung cancer. Read more about Associations of frailty with survival, hospitalization, functional decline, and toxicity among older adults with advanced non-small cell lung cancer.
Palbociclib plus aromatase inhibitors in patients with metastatic breast cancer and cardiovascular diseases: real-world effectiveness. Read more about Palbociclib plus aromatase inhibitors in patients with metastatic breast cancer and cardiovascular diseases: real-world effectiveness.
Health-related quality of life with sacituzumab govitecan in HR+/HER2- metastatic breast cancer in the phase III TROPiCS-02 trial. Read more about Health-related quality of life with sacituzumab govitecan in HR+/HER2- metastatic breast cancer in the phase III TROPiCS-02 trial.
Synchronous or metachronous breast and colorectal cancers in younger-than-average-age patients: a case series. Read more about Synchronous or metachronous breast and colorectal cancers in younger-than-average-age patients: a case series.
HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains. Read more about HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains.
Evaluation of Culture Conducive to Academic Success by Gender at a Comprehensive Cancer Center. Read more about Evaluation of Culture Conducive to Academic Success by Gender at a Comprehensive Cancer Center.
The Landscape of US and Global Rare Tumor Research Programs: A Systematic Review. Read more about The Landscape of US and Global Rare Tumor Research Programs: A Systematic Review.
Left Ventricular Ejection Fraction in Patients With Ovarian Cancer Treated With Avelumab, Pegylated Liposomal Doxorubicin, or Both. Read more about Left Ventricular Ejection Fraction in Patients With Ovarian Cancer Treated With Avelumab, Pegylated Liposomal Doxorubicin, or Both.
Molecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay. Read more about Molecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay.
Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2- Advanced Breast Cancer: Findings From a Multicountry Survey. Read more about Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2- Advanced Breast Cancer: Findings From a Multicountry Survey.
